New drug combo shows promise for hard-to-treat stomach cancer
NCT ID NCT03505320
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a drug called zolbetuximab that targets a protein (CLDN18.2) found in many stomach and gastroesophageal junction tumors. The drug is given alone or with chemotherapy and/or immunotherapy to see how well it controls tumor growth. The study includes 143 adults with advanced cancer that cannot be removed by surgery. The goal is to find better treatment options for people with this type of cancer.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GASTRIC ADENOCARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Mass General / North Shore Can
Boston, Massachusetts, 02114, United States
-
Memorial Sloan Kettering Cancer Center
New York, New York, 10065, United States
-
Site FR33001
Brest, France
-
Site FR33002
Poitiers, New Aquitaine, 86021, France
-
Site FR33003
Pessac, New Aquitaine, 33604, France
-
Site FR33004
Paris, 75015, France
-
Site IT39002
Naples, Italy
-
Site IT39003
Pisa, Italy
-
Site IT39004
Padova, Italy
-
Site IT39005
Milan, Italy
-
Site JP81001
Chiba, Japan
-
Site JP81002
Tokyo, Japan
-
Site JP81003
Tokyo, Japan
-
Site KR82001
Seoul, South Korea
-
Site KR82002
Seongnam-si, South Korea
-
Site TW88601
Taichung, Taiwan
-
Site TW88602
Tainan, 70403, Taiwan
-
The Angeles Clinic and Research Institute
Los Angeles, California, 90025, United States
-
UCLA Medical Center
Santa Monica, California, 90404, United States
-
University of Chicago
Chicago, Illinois, 60637, United States
-
Weill Cornell Medical College
New York, New York, 10065, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a Triple-Drug attack slow down stomach cancer?
- Can a Three-Drug cocktail shrink stomach tumors before surgery?
- Can a new nucleotide analogue boost cancer treatment?
- Can a less extensive stomach surgery preserve appetite better?
- Can a vaccine stop stomach cancer from coming back?
- New drug combo aims to outperform immunotherapy in Hard-to-Treat stomach cancer